Rohto Pharmaceutical Co.,Ltd.
Symbol: 4527.T
JPX
3200
JPYMarket price today
23.2296
P/E Ratio
0.8870
PEG Ratio
730.04B
MRK Cap
- 0.01%
DIV Yield
Rohto Pharmaceutical Co.,Ltd. (4527-T) Financial Statements
Balance Sheet
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 79951 | 72791 | 52964 | ||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 1008 | 661 | -1199 | ||||||||||||||||
balance-sheet.row.net-receivables | 0 | 60656 | 51682 | 47865 | ||||||||||||||||
balance-sheet.row.inventory | 0 | 41062 | 33527 | 27925 | ||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 29547 | 24678 | 20975 | ||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 190246 | 164306 | 133071 | ||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 66182 | 62839 | 49790 | ||||||||||||||||
balance-sheet.row.goodwill | 0 | 2564 | 2954 | 4014 | ||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 6997 | 6338 | 3521 | ||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 9561 | 9292 | 7535 | ||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 32629 | 27471 | 27425 | ||||||||||||||||
balance-sheet.row.tax-assets | 0 | 5371 | 5297 | 4606 | ||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 5686 | 5419 | 3361 | ||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 119429 | 110318 | 92717 | ||||||||||||||||
balance-sheet.row.other-assets | 0 | 2 | 3 | 2 | ||||||||||||||||
balance-sheet.row.total-assets | 0 | 309677 | 274627 | 225790 | ||||||||||||||||
balance-sheet.row.account-payables | 0 | 16025 | 13660 | 9603 | ||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 4177 | 8033 | 2312 | ||||||||||||||||
balance-sheet.row.tax-payables | 0 | 6230 | 3185 | 6138 | ||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 7516 | 13350 | 5787 | ||||||||||||||||
Deferred Revenue Non Current | 0 | 3146 | 3387 | 5126 | ||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 29368 | 27256 | 10008 | ||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 14439 | 19311 | 12708 | ||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 1184 | 1184 | 179 | ||||||||||||||||
balance-sheet.row.total-liab | 0 | 94601 | 90799 | 69179 | ||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.common-stock | 0 | 6504 | 6504 | 6504 | ||||||||||||||||
balance-sheet.row.retained-earnings | 0 | 184005 | 162195 | 145511 | ||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 18705 | 8735 | 3167 | ||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 354 | 851 | 725 | ||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 209568 | 178285 | 155907 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 309677 | 274627 | 225790 | ||||||||||||||||
balance-sheet.row.minority-interest | 0 | 5508 | 5543 | 704 | ||||||||||||||||
balance-sheet.row.total-equity | 0 | 215076 | 183828 | 156611 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||||||
Total Investments | 0 | 33637 | 28132 | 26226 | ||||||||||||||||
balance-sheet.row.total-debt | 0 | 11693 | 21383 | 8099 | ||||||||||||||||
balance-sheet.row.net-debt | 0 | -68258 | -51408 | -44865 |
Cash Flow Statement
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 34290 | 27953 | 23006 | ||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 7801 | 7673 | 6748 | ||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -11277 | 458 | 3402 | ||||||||||||||||
cash-flows.row.account-receivables | 0 | -7560 | -30 | 2464 | ||||||||||||||||
cash-flows.row.inventory | 0 | -6105 | -3061 | 3188 | ||||||||||||||||
cash-flows.row.account-payables | 0 | 1716 | 3323 | -2811 | ||||||||||||||||
cash-flows.row.other-working-capital | 0 | 672 | 226 | 561 | ||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 110 | -8834 | -13148 | ||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -9908 | -11328 | -10304 | ||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -1582 | -1203 | -1516 | ||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -5940 | -5615 | -2206 | ||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 2641 | 1963 | 4050 | ||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 1613 | -223 | -261 | ||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -13176 | -16406 | -10237 | ||||||||||||||||
cash-flows.row.debt-repayment | 0 | -8761 | -3133 | -1880 | ||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.dividends-paid | 0 | -4676 | -3422 | -2965 | ||||||||||||||||
cash-flows.row.other-financing-activites | 0 | -2762 | 10025 | 2498 | ||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -16199 | 3470 | -2347 | ||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 5236 | 4335 | 96 | ||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 6786 | 18651 | 7589 | ||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 77691 | 70905 | 52254 | ||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 70905 | 52254 | 44665 | ||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 30924 | 27250 | 20008 | ||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -9908 | -11328 | -10304 | ||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 21016 | 15922 | 9704 |
Income Statement Row
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 238664 | 199646 | 181053 | ||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 101243 | 83157 | 74326 | ||||||||||||||||
income-statement-row.row.gross-profit | 0 | 137421 | 116489 | 106727 | ||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-expenses | 0 | -63 | 246 | 260 | ||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 103457 | 87135 | 83732 | ||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 204700 | 170292 | 158058 | ||||||||||||||||
income-statement-row.row.interest-income | 0 | 962 | 368 | 341 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 247 | 248 | 145 | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 751 | -240 | 1139 | ||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | -63 | 246 | 260 | ||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 751 | -240 | 1139 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 247 | 248 | 145 | ||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 7801 | 7673 | 6748 | ||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.operating-income | 0 | 33959 | 29349 | 22990 | ||||||||||||||||
income-statement-row.row.income-before-tax | 0 | 34290 | 27953 | 23006 | ||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 7860 | 6803 | 6236 | ||||||||||||||||
income-statement-row.row.net-income | 0 | 26377 | 21127 | 16743 |
Frequently Asked Question
What is Rohto Pharmaceutical Co.,Ltd. (4527.T) total assets?
Rohto Pharmaceutical Co.,Ltd. (4527.T) total assets is 309677000000.000.
What is enterprise annual revenue?
The annual revenue is N/A.
What is firm profit margin?
Firm profit margin is 0.582.
What is company free cash flow?
The free cash flow is 74.691.
What is enterprise net profit margin?
The net profit margin is 0.117.
What is firm total revenue?
The total revenue is 0.154.
What is Rohto Pharmaceutical Co.,Ltd. (4527.T) net profit (net income)?
The net profit (net income) is 26377000000.000.
What is firm total debt?
The total debt is 11693000000.000.
What is operating expences number?
The operating expences are 103457000000.000.
What is company cash figure?
Enretprise cash is 0.000.